article · ALEXMED ePosters
INTRODUCTIONPancreatic cancer has one of the worst prognosis among all malignancies and is projected to become the second leading cause of cancer-related deaths in certain regions. It is the fourth leading cause of cancer-related deaths worldwide. pancreatic cancer has a low 5-year survival rate of 2% to 9%, which remains consistent across both high-income and low- to middle-income countries. This survival rate also varies by location and country, but it never exceeds 10%.Adenocarcinoma is the most common type of pancreatic cancer . The name 'silent killer' has been given to this cancer because it progresses silently, has late clinical signs, and grows rapidly. . AIM OF THE WORKThe main goal of our study was to assess the recent updates in the role of MDCT in prediction of resectability of pancreatic cancerSUBJECTS AND METHODS Target population: The study was carried out on 42 patients with approved manifestations of cancer pancreas who admitted to Alexandria main university hospital and Gamal Abdel Naser insurance hospital for diagnosis and management.Before CT imaging, all individuals were subjected to: I. Informed written consent.II. Full history and clinical examination.III. General and abdominal examinations by the referral clinician.IV. Laboratory investigations.V. Imaging techniques:
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/alexpo.2024.309902.1908
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
